未知生产厂商
GWN-323 is an agonistic anti-GITR monoclonal antibody (GITR agonist) on a human IgG1 scaffold, targeting glucocorticoid-induced TNFR-related protein (GITR). It was clinically evaluated as a single agent and in combination with spartalizumab (anti-PD-1).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
